|Publication number||US5824653 A|
|Application number||US 08/562,932|
|Publication date||Oct 20, 1998|
|Filing date||Nov 27, 1995|
|Priority date||Nov 28, 1994|
|Also published as||DE69515617D1, DE69515617T2, EP0717993A2, EP0717993A3, EP0717993B1|
|Publication number||08562932, 562932, US 5824653 A, US 5824653A, US-A-5824653, US5824653 A, US5824653A|
|Inventors||Vincent Beuvry, Michael Forster|
|Original Assignee||Virbac S.A.|
|Export Citation||BiBTeX, EndNote, RefMan|
|Patent Citations (4), Referenced by (60), Classifications (11), Legal Events (7)|
|External Links: USPTO, USPTO Assignment, Espacenet|
The present invention relates to a composition for the control and the treatment of parasitic infestations in Equidae and, in particular, for simultaneous control and treatment of infestations by roundworms and tapeworms in such animals.
Avermectins and milbemycins are currently used in the treatment and control of roundworms and bots in horses and ponies. However, these compounds are known to be inactive against tapeworms. The widespread use of the anthelmintic ivermectin has recently been linked to a rise in the prevalence of the equine tapeworm Anoplocephala perfoliata.
Anoplocephala perfoliata is found mainly in the caecum but tends also to cluster in the ileum near the ileocecal valve where it is associated with ulceration and reactive inflammation of the ileal wall. This clustering results in ulceration of the mucous membrane and inflammation with thickening and induration of the deeper layers of the intestinal wall. These pathological changes probably account for some cases of persistent diarrhoea and may predispose to intussusception of the ileum into the caecum or rupture of the bowel wall in the vicinity of the ileocecal valve.
It is therefore highly desirable to have a composition which has activity against both cestode and nematode infestations in Equidae and more particularly in horses.
It is accordingly an object of the present invention to provide a novel veterinary composition adapted to control both cestodes and nematodes in equine animals.
According to the invention, there is provided an anthelmintic composition for oral use comprising an effective amount of praziquantel and an effective amount of at least one anthelmintic agent selected from avermectins or milbemycins or derivatives thereof.
Indeed, trials have shown that, when praziquantel is orally administered to horses in combination with an avermectin or a milbemycin or a derivative thereof, a surprising increase of the anthelmintic spectrum is obtained due to the administration in combination. Furthermore a synergistic effect is observed to the extend that when in combination with avermectins or milbemycins the required dosage rate for praziquantel in equine animals is between 0.5 and 2.0 mg per kg of animal body weight. This synergistic activity is even higher with a paste formula.
Anthelmintic formulations containing praziquantel together with another anthelmintic such as for example levamisole, albendazole, oxfendazole, moxidectin, ivermetin, have been disclosed in the British Patent Application 2 252 730 of Ancare Distributors Limited. However, the various associations disclosed in this Patent Application are not synergistic and only increase the anthelmintic spectrum in sheep. According to Ancare Distributors Limited, the recommended dose rate of praziquantel in such associations is between 2.0 and 7.5 mg per kg of animal body weight.
According to the present invention, it has been discovered that the association between praziquantel and an avermectin or a milbemycin or a derivative thereof shows a surprising synergy in the treatment of horse tapeworms. It allowed the use of praziquantel against Anoplocephala perfoliata in Equidae at a dose rate between 0.5 and 2.0 mg per kg of animal body weight. These dosages are significantly lower than in the already described formulations.
Kitano in the European Patent Application 0 059 074 discloses associations of macrolide anthelmintic agents (avermectins) and a variety of several anthelmintic agents like benzimidazole, salicylamide and isoquinoline compounds with enhanced anthelmintic activity. However, Kitano studies on cestodes did not show any evident synergy of any association on Anoplocephala perfoliata.
According to the present invention, the activity of praziquantel against Anoplocephala perfoliata is increased in association with an avermectin or a milbemycin compound or a derivative thereof.
Moreover, the association exhibits higher synergistic activity as a paste formula which allowed a better biodisponibility of praziquantel in horses.
Praziquantel (2(cyclohexylcarbonyl)-1,2,3,6,7,11b-hexahydro-4H-pyrazino 2,1-a!isoquinolin-4-one) is a relatively insoluble material in water and consequently the applicant has devised formulations for administration of the compound subject of this invention in the form of paste, drench, tablet or pellet.
Examples of formulations in accordance with the present invention will be described hereafter without limiting the generality of the invention as above described.
The range of active percentages of a typical formula in accordance with this invention could be as indicated thereafter:
______________________________________ Praziquantel 0.1-30% w/v and Ivermectin 0.05-5% w/v or Abamectin 0.05-5% w/v or Moxidectin 0.05-5% w/v or Doramectin 0.05-5% w/v______________________________________
and one or more of the following ingredients to enhance stability and/or other characteristics of the composition: surfactants, preservatives, viscosity agents, stabilisers, flavours and colours.
Ivermectin is a semisynthetic derivative of avermectins. Ivermectin contains at least 80% of 22,23-dihydroavermectin B1a and less than 20% of 22,23-dihydroavermectin B1b. Ivermectin is disclosed in Australian Patent 519569.
Abamectin or avermectin B1 contains at least 80% of avermectin B1a and not more than 20% of avermectin B1b. Abamectin is disclosed in Australian Patent 513641.
Moxidectin spiro (11,5-methano-2Hm13G, 17H-furo(4,3,2-pg) (2,6) benzodioxacyclo octadectin-13,2'-(2H) pyran-7-one,20,20b-dihydroxy-6'(1,3-dimethyl-T-butenyl)=4'-(methoxymino)-3',4',5',6,6',7,10,11,14,15,17a,20,20a, 20b-tetradecahydro-5'6,8,19-teramethyl-(6R-(2aZ,4E,5'S*, 6R* (E),8E,11R*,13S*,15R*,17aR*,20R*,20bS*)! is a new broad spectrum endectocide.
Doramectin (25-cyclohexyl-5-O-demethyl-25-de-1(methylpropyl)avermectin A1a is an avermectin.
According to the invention, when praziquantel is orally administered in combination with an avermectin, a milbemycin or a derivative thereof, the dosage rate of praziquantel required for efficiently treating equine animals against nematodes and more particularly against Anoplocephala perfoliata is between 0.5 and 2.0 mg per kg of animal body weight. However, it has been observed that praziquantel may be administered in higher dosage rates without adverse effects and in this regard dosage rates of up to 7.5 mg per kg of body weight have been tested.
______________________________________ABAMECTIN (AVERMECTIN B1) 0,4 gPRAZIQUANTEL 50 gDIETHYLENE GLYCOL PALMITO STEARATE 80 gSODIUM METABISULFITESORBITOL SOLUTION (NON-CRYSTALLISING) 120 gGLYCEROL FORMAL 60 mlPOLYETHYLENE GLYCOL 400 60 mlMETHYL HYDROXYBENZOATE 0,5 gPROPYL HYDROXYBENZOATE 0,05 gBENZYL ALCOHOL 10 gOAT MEAL FLOUR 300 gPURIFIED WATER q.s. to 1 liter______________________________________
The manufacture of the formulations of Example 1 is in accordance with the following procedures:
1. Heat 400 ml of purified water in a separate container to 80 degrees-85 degrees Celsius.
2. While mixing, add and dissolve methyl hydroxybenzoate and propyl hydroxybenzoate. Continue mixing until all has dissolved.
3. While mixing, add Sorbitol solution. Maintain the temperature at 70 degrees Celsius.
4. In a separate container, add glycerol formal, polyethylene glycol 400, benzyl alcohol. Start mixing while warming to 35 degrees-40 degrees Celsius.
5. While mixing, add abamectin. Continue mixing until all has dissolved. Maintain temperature at 35 degrees-40 degrees Celsius.
6. In the ointment tank, add half of the Oat Flour, the praziquantel, then start mixing. Continue mixing for 5-10 minutes until a homogeneous blended powder is formed. The add the rest of the Oat Flour and continue mixing.
7. While mixing the powders, add the solution from step 5 in a thin stream. When all is added, continue mixing until an homogenous mass is formed.
8. Melt diethylene glycol palmitostearate in a separate container. While mixing the solution form step 3, add the melted wax and continue mixing to form an homogeneous emulsion. Stop heating and mix to cool to 40 degrees-45 degrees Celsius.
9. Add and dissolve sodium metabisulphite in the emulsion.
10. While mixing the mass from step 7, add gradually and in a thin stream the emulsion from step 9. The emulsion when added should be at 40 degrees-45 degrees Celsius.
11. When all is added, continue mixing for 10-15 minutes.
12. Complete the batch to volume with purified water while mixing. Continue mixing for 30 minutes. Stop when the batch temperature is not higher than 30 degrees Celsius. Check on Specific Gravity (1.05-1.09).
13. Homogenise the batch.
14. Pack in syringes.
Combinations with other avermectins or milbemycin type compounds can be formulated in a manner similar to that of Example 1.
We use the ingredients, dosages and manufacturing process for Example 1 except for abamectin which is used in an amount of 2 g instead of 0.4 g.
We use the ingredients, dosages and manufacturing process of Example 1 except for abamectin which is used in an amount of 4 g instead of 0.4 g.
We use the ingredients, dosages and manufacturing process of Example 1 except for abamectin which is used in an amount of 8 g instead of 0.4 g.
We use the ingredients, dosages and manufacturing process of Example 1 except for abamectin which is used in an amount of 20 g instead of 0.4 g.
______________________________________IVERMECTIN 2 gPRAZIQUANTEL 50 gGLYCEROL FORMAL 250 mlTWEEN 80 120 gBENZYL ALCOHOL 30 gXANTHAM GUM 1 gPURIFIED WATER q.s. to 1 liter______________________________________
Other Avermectins such as abamectin or doramectin or milbemycins such as moxidectin may be used in place of ivermectin.
We use the ingredients, dosages and manufacturing process of Example 6 except for ivermectin which is used in an amount of 4 g instead of 2 g.
We use the ingredients, dosages and manufacturing process of Example 6 except for ivermectin which is used in an amount of 8 g instead of 2 g.
1 Tablet/200 kg body weight
______________________________________ Per Tablet______________________________________ABAMECTIN 40 mgPRAZIQUANTEL 200 mgSODIUM STARCH GLYCOLLATE 12 gHYDROXY PROPYL CELLULOSE 4 mgLACTOSE 178 mgCOLLOIDAL SILICON DIOXIDE 4 mgMAGNESIUM STEARATE 2 mg______________________________________
Other avermectins or milbemycins can be used instead of abamectin.
Trials of formulations in accordance with the present invention have been conducted in Australia.
The method of evaluating the activity of the formulation was a modified critical test (Lyons et al., 1986) which involved killing the horses 24 hours after treatment.
Efficacy is the number of worms count dead and removed versus the number of worms count alive and not removed (scolex attached for Anaplocephala perfoliata).
A trial involving abamectin paste (1 ml per 20 kg of body weight equivalent to 0.2 mg of Abamectin per kg B.W.), praziquantel paste (0.1 to 5 mg of Praziquantel per kg of body weight), and formulations in accordance with examples 1,2,3,4 and 5.
Eleven groups of ten horses per group were involved in the study. Area of origin of the horses was well known for having internal parasitism problem and specifically tapeworms (Anoplocephala perfoliata) infestation.
A high level of efficacy was demonstrated by the combination formula of Examples 2, 3, 4 and 5 against roundworms, anthropod parasites and tapeworms.
Synergistic activity of praziquantel and abamectin shows 100% removal of Anoplocephala perfoliata with 0.2 mg of abamectin per kg B.W. and 1 mg of praziquantel per kg B.W.
__________________________________________________________________________ % Efficacy Dosage % Efficacy % Efficacy % Efficacy AnoplocephalaAnthelmintic mg/kg Strongylidase Gasterophilus spp. Parascaris equorum perfoliata__________________________________________________________________________Abamectin 0.2 100 100 100 0Praziquantel 0.1 0 0 0 0Praziquantel 0.5 0 0 0 27Praziquantel 1 0 0 0 51Praziquantel 2 0 0 0 71Praziquantel 5 0 0 0 33Abamectin 0.2 100 100 100Praziquantel 0.1 39Abamectin 0.2 100 100 100Praziquantel 0.5 89Abamectin 0.2 100 100 100Praziquantel 1 100Abamecitin 0.2 100 100 100Praziquantel 2 100Abamectin 0.2 100 100 100Praziquantel 5 100__________________________________________________________________________
A trial involving Ivermectin drench (1 ml per 10 kg of body weight equivalent to 0.2 mg of Ivermectin per kg B.W.), praziquantel drench (0.5 to 2 mg of praziquantel per kg of body weight), and formulations in accordance with Examples 6, 7 and 8.
Seven groups of 6 horses per group were involved in the study. Area of origin of the horses was well known for having internal parasitism problem and specifically tapeworms (Anoplocephala perfoliata) infestation.
A high level of efficacy was demonstrated by the combination formula of Examples 7 and 8 against roundworms, arthropod parasites and tapeworms.
Synergistic activity of praziquantel and ivermectin shows 100% removal of Anoplocephala perfoliata with 0.2 mg of ivermectin per kg B.W. and 2 mg of praziquantel per kg B.W.
__________________________________________________________________________ % Efficacy Dosage % Efficacy % Efficacy % Efficacy AnoplocephalaAnthelmintic mg/kg Strongylidase Gasterophilus spp. Parascaris equorum perfoliata__________________________________________________________________________Ivermectin 0.2 100 100 100 0Praziquantel 0.5 0 0 0 21Praziquantel 1 0 0 0 43Praziquantel 2 0 0 0 59Ivermectin 0.2 100 100 100Praziquintel 0.5 68Ivermectin 0.2 100 100 100Praziquantel 1 91Ivermectin 0.2 100 100 100Praziquantel 2 100__________________________________________________________________________
|Cited Patent||Filing date||Publication date||Applicant||Title|
|US4624945 *||Aug 9, 1985||Nov 25, 1986||Alza Corporation||Dispensing system with means for increasing delivery of beneficial agent from the system|
|DE3619030A1 *||Jun 6, 1986||Dec 10, 1987||Bayer Ag||Compositions for topical use|
|WO1995005181A2 *||Jul 21, 1994||Feb 23, 1995||Biovet Joint Stock Co||Drug for parasitic control of animals|
|ZA842571A *||Title not available|
|Citing Patent||Filing date||Publication date||Applicant||Title|
|US6025357 *||Jan 3, 1997||Feb 15, 2000||Bayer Aktiengesellschaft||Anthelmintic paste|
|US6165987 *||Jul 25, 1997||Dec 26, 2000||Harvey; Colin Manson||Anthelmintic formulations|
|US6207179||May 18, 2000||Mar 27, 2001||Phoenix Scientific, Inc.||Parasiticidal formulation for animals and a method of making this formulation|
|US6429211||May 23, 2000||Aug 6, 2002||Bayer Corporation||Praziquantel compounds for treating diseases due to Sarcocystis Neospora Toxoplasma and Isospora|
|US6503536||Jul 4, 1997||Jan 7, 2003||Bayer Aktiengesellschaft||Granulates of hexahydropyrazine derivatives which can be administered orally|
|US6627613||Jul 23, 2001||Sep 30, 2003||Michael A. Strobel||Application of water and organic solvent soluble ivermectin for topical and oral use|
|US6733767||Mar 18, 1999||May 11, 2004||Merck & Co., Inc.||Liquid polymeric compositions for controlled release of bioactive substances|
|US6858601||Jul 21, 2003||Feb 22, 2005||Phoenix Scientific, Inc.||Parasiticidal formulation for animals|
|US6893652||Jul 24, 2002||May 17, 2005||Wyeth||Endoparasiticidal gel composition|
|US7001889 *||Jun 21, 2002||Feb 21, 2006||Merial Limited||Anthelmintic oral homogeneous veterinary pastes|
|US7396819||Aug 8, 2003||Jul 8, 2008||Virbac Corporation||Anthelmintic formulations|
|US7396820||Mar 12, 2004||Jul 8, 2008||Virbac Corporation||Anthelmintic formulations|
|US7563773||Apr 15, 2005||Jul 21, 2009||Merial Limited||Anthelmintic oral homogeneous veterinary pastes|
|US7582612||Aug 3, 2004||Sep 1, 2009||Hartz Mountain Corporation||Multi-action anthelmintic formulations|
|US7671034||Mar 1, 2004||Mar 2, 2010||Merial Limited||Stabilized formulation of ivermectin feed premix with an extended shelf life|
|US7674475||Dec 24, 2004||Mar 9, 2010||Wyeth Llc||Endoparasiticidal gel composition|
|US7678383 *||Jun 14, 2002||Mar 16, 2010||Novartis Ag||Aminoacetonitrile compounds for controlling endoparasites|
|US7754696||Dec 6, 2007||Jul 13, 2010||Pharmaceutical Solutions, Inc.||Application of water and organic solvent soluble Ivermectin for topical and oral use|
|US8241669 *||Jan 22, 2010||Aug 14, 2012||Wyeth Llc||Endoparasiticidal gel composition|
|US20030236203 *||Jun 21, 2002||Dec 25, 2003||Keith Freehauf||Anthelmintic oral homogeneous veterinary pastes|
|US20040077703 *||Jul 14, 2003||Apr 22, 2004||Soll Mark D.||Nodulisporic acid derivative spot-on formulations for combating parasites|
|US20040146557 *||Jan 8, 2004||Jul 29, 2004||Chern Rey T.||Liquid polymeric compositions for controlled release of bioactive substances|
|US20040209950 *||Jun 14, 2002||Oct 21, 2004||Pierre Ducray||Amenoacetonitrile compounds for controlling endoparasites|
|US20050032718 *||Aug 8, 2003||Feb 10, 2005||Michael Burke||Anthelmintic formulations|
|US20050136087 *||Mar 1, 2004||Jun 23, 2005||Freehauf Keith A.||Stabilized formulation of ivermectin feed premix with an extended shelf life and method of making the same|
|US20050176657 *||Apr 15, 2005||Aug 11, 2005||Merial Limited||Anthelmintic oral homogeneous veterinary pastes|
|US20050203034 *||Aug 3, 2004||Sep 15, 2005||Albert Ahn||Multi-action anthelmintic formulations|
|US20050245468 *||Feb 1, 2005||Nov 3, 2005||Wyeth||Anthelmintic composition|
|US20060205681 *||Dec 20, 2005||Sep 14, 2006||Maryam Moaddeb||Homogenous paste formulations|
|US20070065463 *||Jun 21, 2004||Mar 22, 2007||Ronald Aung-Din||Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions|
|US20080027011 *||Mar 5, 2007||Jan 31, 2008||Hassan Nached||Homogeneous paste and gel formulations|
|US20080090899 *||Dec 6, 2007||Apr 17, 2008||Pharmaceutical Solutions, Inc.||Application of water and organic solvent soluble ivermectin for topical and oral use|
|US20100087497 *||Apr 8, 2010||Wyeth||Benzimidazole Anthelmintic Compositions|
|US20100120782 *||Jan 22, 2010||May 13, 2010||Wyeth Llc||Endoparasiticidal gel composition|
|US20100197571 *||May 28, 2008||Aug 5, 2010||Bayer Animal Health Gmbh||Extrudates with improved taste masking|
|CN1681482B||Aug 14, 2003||Oct 17, 2012||梅瑞尔有限公司||Animal remedy preparation without animal products|
|CN102133173A *||Mar 3, 2011||Jul 27, 2011||浙江海正药业股份有限公司||Moxidectin pour sprinkling preparation and preparation method thereof|
|CN102133173B||Mar 3, 2011||Apr 3, 2013||浙江海正药业股份有限公司||Moxidectin pour sprinkling preparation and preparation method thereof|
|EP2465851A1||Jul 3, 2007||Jun 20, 2012||Aventis Agriculture||1-Aryl-5-alkyl pyrazole derivative compounds, processes of making and methods of using thereof|
|EP2550962A2||Nov 13, 2009||Jan 30, 2013||Merial Limited||Compositions comprising an aryl pyrazole and/or a formamidine, methods and uses thereof|
|EP2639228A2||May 12, 2008||Sep 18, 2013||Merial Limited||Aryloazol-2-yl cyanoethylamino compounds, method of making and method of using thereof|
|WO2004000034A2 *||Jun 13, 2003||Dec 31, 2003||Merial Llc||Anthelmintic oral homogeneous veterinary pastes|
|WO2005063015A1||Dec 17, 2004||Jul 14, 2005||Merial Ltd||Stabilized formulation of ivermerctin feed premix|
|WO2009062939A1||Nov 12, 2008||May 22, 2009||Novartis Ag||Anthelmintic paste comprising praziquantel, a macrolide lactone, cyclodextrin and a thickener|
|WO2011069143A1||Dec 5, 2010||Jun 9, 2011||Merial Limited||Pesticidal bis-organosulfur compounds|
|WO2011075591A1||Dec 16, 2010||Jun 23, 2011||Merial Limited||Anti parasitic dihydroazole compounds and compositions comprising same|
|WO2011123773A1||Apr 1, 2011||Oct 6, 2011||Merial Limited||Parasiticidal compositions comprising multiple active agents, methods and uses thereof|
|WO2012068202A1||Nov 16, 2011||May 24, 2012||Centre National De La Recherche Scientifique (Cnrs)||Novel monensin derivatives for the treatment and prevention of protozoal infections|
|WO2013003168A1||Jun 21, 2012||Jan 3, 2013||Merial Limited||Novel insect-repellent coumarin derivatives, syntheses, and methods of use|
|WO2013003505A1||Jun 27, 2012||Jan 3, 2013||Merial Limited||Amido-pyridyl ether compounds and compositions and their use against parasites|
|WO2013039948A1||Sep 12, 2012||Mar 21, 2013||Merial Limited||Parasiticidal compositions comprising an isoxazoline active agent, methods and uses thereof|
|WO2013044118A2||Sep 21, 2012||Mar 28, 2013||Merial Limited||Indirect modeling of new repellent molecules active against insects, acarids, and other arthropods|
|WO2013074892A1||Nov 16, 2012||May 23, 2013||Merial Limited||Compositions comprising an aryl pyrazole and a substituted imidazole, methods and uses thereof|
|WO2013119442A1||Jan 31, 2013||Aug 15, 2013||Merial Limited||Parasiticidal oral veterinary compositions comprising systemically-acting active agents, methods and uses thereof|
|WO2013126694A1||Feb 22, 2013||Aug 29, 2013||Merial Limited||Topical compositions comprising fipronil and permethrin and methods of use|
|WO2013158894A1||Apr 18, 2013||Oct 24, 2013||Merial Limited||Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof|
|WO2014081697A2||Nov 19, 2013||May 30, 2014||Merial Limited||Anthelmintic compounds and compositions and method of using thereof|
|WO2014121064A1||Jan 31, 2014||Aug 7, 2014||Merial Limited||Method for treating and curing leishmaniosis using fexinindazole|
|WO2015066277A1||Oct 30, 2014||May 7, 2015||Merial Limited||Antiparisitic and pesticidal isoxazoline compounds|
|WO2015161224A1||Apr 17, 2015||Oct 22, 2015||Merial, Inc.||Use of malononitrile compounds for protecting animals from parasites|
|U.S. Classification||514/30, 514/450|
|International Classification||A61K31/70, A61K31/495, A61K31/7048, A01N43/90, A61K31/365, A61K, A61K31/335|
|Jul 24, 1996||AS||Assignment|
Owner name: VIRBAC S.A., FRANCE
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:BEUVRY, VINCENT;FORSTER, MICHAEL;REEL/FRAME:008050/0207;SIGNING DATES FROM 19960410 TO 19960417
|Oct 5, 1999||CC||Certificate of correction|
|Apr 4, 2002||FPAY||Fee payment|
Year of fee payment: 4
|Mar 30, 2006||FPAY||Fee payment|
Year of fee payment: 8
|Oct 2, 2006||AS||Assignment|
Owner name: FIRST BANK, MISSOURI
Free format text: AMENDMENT TO SECURITY AGREEMENT;ASSIGNOR:VIRBAC AH, INC.;REEL/FRAME:018338/0015
Effective date: 20060629
Owner name: J.P. MORGAN CHASE BANK, N.A., NEW YORK
Free format text: AMENDMENT TO SECURITY AGREEMENT;ASSIGNOR:VIRBAC AH, INC.;REEL/FRAME:018338/0015
Effective date: 20060629
|May 23, 2007||AS||Assignment|
Owner name: VIRBAC AH, INC., TEXAS
Free format text: RELEASE BY SECURED PARTY;ASSIGNOR:FIRST BANK;REEL/FRAME:019331/0221
Effective date: 20070522
|Apr 20, 2010||FPAY||Fee payment|
Year of fee payment: 12